MENLO PARK, Calif., June 19, 2012 /PRNewswire/ -- Auxogyn, Inc., a company at the forefront of reproductive health innovation, today announced the commencement of a groundbreaking research study with Reproductive Medicine Associates of New Jersey (RMANJ), an internationally-renowned fertility clinic that has pioneered and successfully implemented cutting-edge clinical advancements to more accurately detect healthy embryos for patients undergoing in vitro fertilization (IVF).
"Auxogyn is committed to funding and conducting rigorous scientific research to continually improve outcomes for IVF patients," said Lissa Goldenstein, president and chief executive officer of Auxogyn. "We are pleased to partner with RMANJ and believe this study may expand our understanding of embryo development dramatically, potentially leading to further improvement in our ability to detect healthy embryos during assisted reproduction procedures."
Patients enrolled in the study will be those who have determined, after consultation with their physician, to undergo pre-implantation genetic diagnosis using Comprehensive Chromosome Screening (CCS), a new rapid-method 24-chromosome screening technique first implemented at RMANJ. During the study, all embryos will be monitored using the Eeva™ (Early Embryo Viability Assessment) Test, a non-invasive test developed by Auxogyn to record and quantitatively analyze embryo development against scientifically- and clinically-validated cell-division time periods.
"Our objectives at RMANJ are two-fold: to increase the healthy live birth rate for those undergoing assisted reproductive procedures, and to decrease the multiple embryo transfer rate, thereby reducing multiple pregnancies," commented Richard T. Scott, Jr., M.D., F.A.C.O.G., H.C.L.D., founding partner of RMANJ. "T
|SOURCE Auxogyn, Inc.|
Copyright©2012 PR Newswire.
All rights reserved